Form 4: Hillhouse Entities Divest Over 555K AVBP Shares

Hillhouse Investment Management and HHLR Advisors reported the sale of over 555,000 ArriVent BioPharma common shares for $23.37 each.

Summary

• Hillhouse Investment Management, Ltd. and HHLR Advisors, Ltd., both 10% owners and directors of ArriVent BioPharma, Inc. (AVBP), jointly filed a Form 4.
• The filing reports the sale of 555,555 shares of ArriVent BioPharma common stock.
• The transaction occurred on December 10, 2025, at a price of $23.37 per share.
• Following the sale, the reporting persons indirectly beneficially own 3,929,117 shares of ArriVent BioPharma common stock.
• The sold shares were held by HACF, L.P., where HHLR Advisors, Ltd. acts as the sole management company.
• The remaining shares are held by VSUM VI Holdings Limited, VSUM VIII Holdings Limited, and ARVT Holdings Limited, managed by Hillhouse Investment Management, Ltd. for their respective parent funds.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal, as significant insider selling by a 10% owner and director can suggest a tempered outlook on the company's near-term prospects or valuation.

Negatives

• A significant insider sale of 555,555 shares by a 10% owner and director.
• The sale price of $23.37 per share indicates the price at which the insider chose to divest.

Risks

• Insider selling can sometimes signal a lack of confidence in the company's future prospects by those with intimate knowledge.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that insider selling, especially by significant shareholders and directors in the biopharma sector, can sometimes be interpreted by the market as a signal regarding future company performance or valuation, particularly given the inherent risks and long development cycles in the industry.

Related Party Transactions

• The sale of 555,555 shares was from HACF, L.P., where HHLR Advisors, Ltd. acts as the sole management company.
• The remaining 3,929,117 shares are held by VSUM VI Holdings Limited, VSUM VIII Holdings Limited, and ARVT Holdings Limited, where Hillhouse Investment Management, Ltd. acts as the sole management company for their respective parent funds.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, potentially impacting investor sentiment and share price.

Key Dates

Recommendation

The sale of a significant block of shares by a 10% owner and director, Hillhouse Investment Management and HHLR Advisors, suggests a cautious stance from a key insider. While not a complete divestment, this transaction could signal a belief that the stock's current valuation is fair or that near-term growth prospects are limited. Investors should monitor future insider activity and company developments closely, but the remaining substantial indirect ownership suggests continued, albeit reduced, interest.

Keywords

ArriVent BioPharma, AVBP, Hillhouse Investment Management, HHLR Advisors, Insider Sale, Form 4, Beneficial Ownership, Equity Transaction, Biopharma